PriceTargets.com logo

Kardigan - KARD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $42.25
  • Forecasted Upside: 111.04%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$20.02 As of 08/28/2026 05:00 PM ET
▼ -0.78 (-3.75%)

This chart shows the closing price for KARD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kardigan Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KARD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KARD

Analyst Price Target is $42.25
▲ +111.04% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Kardigan in the last 3 months. The average price target is $42.25, with a high forecast of $46.00 and a low forecast of $37.00. The average price target represents a 111.04% upside from the last price of $20.02.

This chart shows the closing price for KARD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in Kardigan.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/25/2026JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$51.00 ➝ $46.00
7/15/2026Zacks ResearchUpgradeHold
7/13/2026TD CowenInitiated CoverageBuy$46.00
7/13/2026Jefferies Financial GroupInitiated CoverageBuy$40.00
7/13/2026TD CowenInitiated CoverageBuy$46.00
7/13/2026Jefferies Financial GroupInitiated CoverageBuy$40.00
7/13/2026Leerink PartnersInitiated CoverageOutperform$37.00
7/13/2026JPMorgan Chase & Co.Initiated CoverageOverweight$51.00
(Data available from 8/28/2021 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/30/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2026

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Kardigan

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.
Read More

Today's Range

Now: $20.02
Low: $19.99
High: $20.93

50 Day Range

MA: $21.92
Low: $19.82
High: $25.90

52 Week Range

Now: $20.02
Low: $16.25
High: $27.00

Volume

196,556 shs

Average Volume

351,350 shs

Market Capitalization

$1.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Kardigan?

The following Wall Street analysts have issued research reports on Kardigan in the last year: Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, TD Cowen, Wall Street Zen, and Zacks Research.
View the latest analyst ratings for KARD.

What is the current price target for Kardigan?

0 Wall Street analysts have set twelve-month price targets for Kardigan in the last year. Their average twelve-month price target is $42.25, suggesting a possible upside of 111.0%. JPMorgan Chase & Co. has the highest price target set, predicting KARD will reach $46.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $37.00 for Kardigan in the next year.
View the latest price targets for KARD.

What is the current consensus analyst rating for Kardigan?

Kardigan currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KARD.

What other companies compete with Kardigan?

Other companies that are similar to Kardigan include Rhythm Pharmaceuticals, Oruka Therapeutics, CG Oncology, Scholar Rock and Mirum Pharmaceuticals. Learn More about companies similar to Kardigan.

How do I contact Kardigan's investor relations team?

Kardigan's physical mailing address is 506 Carnegie Center Drive Suite 201, Princeton, NJ 08540, US. The company's listed phone number is 415-573-3220 and its investor relations email address is [email protected]. The official website for Kardigan is www.kardigan.bio. Learn More about contacing Kardigan investor relations.